Advertisement

Topics

Safety Study of Avastin Used as Adjunctive Therapy in Pterygium Surgery

2014-08-27 03:14:00 | BioPortfolio

Summary

This study will evaluate the efficacy and safety of the use of bevacizumab (Avastin) as an adjunctive medication during pterygium surgery in preventing pterygium recurrence. A pterygium is a white fleshy growth on the surface of the eye, which can be removed surgically. However, after surgical removal, pterygia can recur. One way of minimizing recurrence is by applying a medication called mitomycin C to the surface of the eye during pterygium surgery. However, mitomycin is associated with certain side effects, such as thinning of the eye wall and poor wound healing. Bevacizumab has a different mechanism of action and there is some evidence that it may be useful in preventing pterygium recurrence. In this study, the safety and efficacy of adjunctive intraoperative use of bevacizumab and mitomycin C for preventing pterygium recurrence will be directly compared.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Conditions

Pterygium

Intervention

Bevacizumab, Mitomycin C

Location

Robert Cizik Eye Clinic
Houston
Texas
United States
77030

Status

Not yet recruiting

Source

The University of Texas Health Science Center, Houston

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:14:00-0400

Clinical Trials [1044 Associated Clinical Trials listed on BioPortfolio]

Pterygium Head Body MMC1: Two Different Surgical Procedures and Their Effect on Endothelial Cell Count.

To evaluate changes in endothelial cell count after pterygium surgery with mitomycin C (MMC) 0.02%

Outpatient Performed Pterygium Surgery Study

This is a randomized controlled trial of postoperative bevacizumab or 5-fluorouracil subconjunctival injections vs placebo for the recurrence of pterygia after excision using conjunctival ...

Subconjunctival Injection of Triamcinolone Acetonide and Limited Peritomy During Pterygium Excision

Pterygium is characterized by encroachment of a fleshy fibrovascular tissue from the bulbar conjunctiva on to the cornea. Although previously thought to be a solely degenerative disease, ...

Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium

1. CBT-001 administered three times daily (TID) for 4 weeks has an acceptable safety profile when used in pterygium patients 2. CBT-001 administered TID for 4 weeks is more effecti...

Effect of Pterygium Excision on Intraocular Lens Power Calculation for Subsequent Cataract Operation

Pterygium is known to induce with-the-rule astigmatism. Excision of pterygium will steepen the cornea and reduce corneal astigmatism. We postulate that the alteration of keratometry readin...

PubMed Articles [215 Associated PubMed Articles listed on BioPortfolio]

Combined Tenonplasty and Scleral Graft for Refractory Scleritis Following Pterygium Removal with Mitomycin C Application.

To report a surgical approach combining scleral patch graft and tenonplasty for successful management of refractory Pseudomonas scleritis following pterygium removal with mitomycin C application.

Systemic Absorption of Mitomycin-C When Used in Pterygium Surgery.

To determine whether scleral topical application of mitomycin-C (MMC) results in measurable plasma levels of systemic absorption.

The Association of MMP-8 Genotypes with Pterygium.

Pterygium is composed of proliferating fibrovascular tissue, and its formation and progression are closely related to the homeostasis of the extracellular microenvironment. However, few studies have e...

Efficacy and Safety of Bevacizumab Combined with Mitomycin C or 5-Fluorouracil in Primary Trabeculectomy: A Meta-Analysis of Randomized Clinical Trials.

The objective of this study was to evaluate the efficacy and safety of bevacizumab combined with antimetabolite as an adjunctive therapy in primary trabeculectomy for glaucoma.

p53 inhibition by MDM2 in human pterygium.

To confirm that mouse double minute 2 (MDM2) could inhibit p53 activity in human pterygium. And to show the disruption of MDM2-p53 interaction could reactive the functions of p53 in pterygium.

Medical and Biotech [MESH] Definitions

Toxic antibiotic of the mitomycin group, obtained from MITOMYCIN and also from Streptomyces ardus and other species. It is proposed as an antineoplastic agent, with some antibiotic properties.

An anti-VEGF recombinant monoclonal antibody consisting of humanized murine antibody. It inhibits VEGF receptors and prevents the proliferation of blood vessels.

An enediyne that alkylates DNA and RNA like MITOMYCIN does, so it is cytotoxic.

An abnormal triangular fold of membrane in the interpalpebral fissure, extending from the conjunctiva to the cornea, being immovably united to the cornea at its apex, firmly attached to the sclera throughout its middle portion, and merged with the conjunctiva at its base. (Dorland, 27th ed)

An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.

More From BioPortfolio on "Safety Study of Avastin Used as Adjunctive Therapy in Pterygium Surgery"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...


Searches Linking to this Trial